BTIG Maintains a Buy Rating on Loxo Oncology (LOXO) and $75.0000 Target; Amphastar Pharmaceuticals (AMPH) Has 1.32 Sentiment

June 6, 2017 - By Maria Brooks

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $782.57 million. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. It has a 89.68 P/E ratio. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients products.

Among 5 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Loxo Oncology Inc has $59 highest and $24 lowest target. $37.33’s average target is -46.76% below currents $70.12 stock price. Loxo Oncology Inc had 14 analyst reports since July 29, 2015 according to SRatingsIntel. Citigroup initiated Loxo Oncology Inc (NASDAQ:LOXO) on Monday, January 18 with “Buy” rating. The stock of Loxo Oncology Inc (NASDAQ:LOXO) earned “Buy” rating by Citigroup on Wednesday, March 16. Cowen & Co maintained Loxo Oncology Inc (NASDAQ:LOXO) on Thursday, August 27 with “Outperform” rating. The stock of Loxo Oncology Inc (NASDAQ:LOXO) earned “Buy” rating by Jefferies on Wednesday, February 8. The rating was maintained by Oppenheimer on Tuesday, August 4 with “Buy”. The firm has “Buy” rating by Citigroup given on Friday, January 15. The firm has “Buy” rating given on Monday, June 5 by Citigroup. The firm has “Sell” rating given on Friday, August 28 by Zacks. The firm has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, March 16.

The stock decreased 0.47% or $0.08 during the last trading session, reaching $17.06. About shares traded. Amphastar Pharmaceuticals Inc (AMPH) has risen 8.19% since June 6, 2016 and is uptrending. It has underperformed by 8.51% the S&P500.

Eam Investors Llc holds 0.42% of its portfolio in Amphastar Pharmaceuticals Inc for 173,018 shares. Globeflex Capital L P owns 50,686 shares or 0.23% of their US portfolio. Moreover, Kalmar Investments Inc De has 0.23% invested in the company for 240,648 shares. The Massachusetts-based Essex Investment Management Co Llc has invested 0.19% in the stock. Oberweis Asset Management Inc, a Illinois-based fund reported 27,200 shares.

Since December 19, 2016, it had 1 buy, and 3 insider sales for $4.11 million activity. Flaherty Keith T. had sold 7,250 shares worth $219,168 on Monday, December 19. Shares for $4.96 million were bought by AISLING CAPITAL III LP.

Investors sentiment increased to 2.41 in 2016 Q4. Its up 0.31, from 2.1 in 2016Q3. It increased, as 7 investors sold Loxo Oncology Inc shares while 15 reduced holdings. 20 funds opened positions while 33 raised stakes. 20.34 million shares or 0.53% less from 20.45 million shares in 2016Q3 were reported. Sg Americas Securities Lc holds 0% or 8,595 shares in its portfolio. State Street Corporation holds 214,321 shares or 0% of its portfolio. Pennsylvania-based Nationwide Fund Advisors has invested 0% in Loxo Oncology Inc (NASDAQ:LOXO). Swiss Retail Bank has 18,700 shares for 0% of their portfolio. Proshare Advsrs Limited Liability Co reported 16,463 shares stake. Hamilton Lane Ltd Liability Company reported 0.39% stake. Prtnrs Holding Ag has 0.06% invested in Loxo Oncology Inc (NASDAQ:LOXO) for 11,894 shares. Blackrock has 1,533 shares for 0% of their portfolio. Awm Investment has invested 1.13% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO). Invesco Ltd has 28,269 shares. Blackrock Advsr Lc reported 6,726 shares stake. American Intl Gru invested 0% in Loxo Oncology Inc (NASDAQ:LOXO). Eam Investors Ltd Liability Co, California-based fund reported 111,268 shares. Gsa Capital Limited Liability Partnership has 13,900 shares for 0.03% of their portfolio. Tiaa Cref Mngmt Ltd holds 0% or 37,158 shares in its portfolio.

The stock increased 43.16% or $21.14 during the last trading session, reaching $70.12. About 78 shares traded. Loxo Oncology Inc (NASDAQ:LOXO) has risen 77.12% since June 6, 2016 and is uptrending. It has outperformed by 60.42% the S&P500.